The Market Reports

Synopsis

The global market for Ursodeoxycholic Acid was estimated to be worth US$ 583 million in 2024 and is forecast to a readjusted size of US$ 995 million by 2031 with a CAGR of 8.7% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Ursodeoxycholic Acid cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Ursodeoxycholic Acid is also known as ursodiol (USAN). Ursodeoxycholic acid (3α, 7β-2-hydroxy-5β-bile acid, UDCA) was first found in the bile of a black bear. Ursodeoxycholic Acid is an important clinical drug in the treatment of gallstones, cholecystitis, PBC, and PSC and has broad market prospects. In previous work, ursodeoxycholic acid was prepared by traditional organic synthesis. In this report, the Ursodeoxycholic Acid we mentioned is Ursodeoxycholic Acid API. In addition, the CAS number is 128-13-2.

The growing prevalence of liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and certain forms of liver cirrhosis, serves as a significant driver for the Ursodeoxycholic Acid (UDCA) market. As more individuals are diagnosed with these conditions due to improved medical awareness and diagnostic techniques, the demand for effective treatments like UDCA increases. UDCA has demonstrated efficacy in managing and alleviating symptoms of these liver diseases, positioning it as a valuable therapeutic option. The rising global burden of liver disorders, often associated with factors like aging and lifestyle changes, provides a sustained demand for UDCA as a key component in manufacturing medications to address these conditions.

One of the major challenges faced by the UDCA API market is the high cost of production, which can limit accessibility, especially in developing regions. The complex extraction and synthesis process of UDCA contributes to its expensive manufacturing, making it difficult for pharmaceutical companies to offer cost-effective treatments. Additionally, regulatory hurdles and stringent quality standards for drug approval add further pressure on manufacturers, which may slow down market growth.

APAC is the largest consumption place, with a consumption market share nearly 52% in 2023. Following APAC, Europe is the second largest consumption place with the consumption market share of 30%.

Global key Ursodeoxycholic Acid players cover ICE, Dipharma Francis, Daewoong Chemical, Zhongshan Bailing, PharmaZell GmbH, Suzhou Tianlv, etc. In terms of revenue, the global five largest companies occupied for a share nearly 81% in 2024.
This report aims to provide a comprehensive presentation of the global market for Ursodeoxycholic Acid, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Ursodeoxycholic Acid by region & country, by Type, and by Application.

The Ursodeoxycholic Acid market size, estimations, and forecasts are provided in terms of sales volume (Tons) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ursodeoxycholic Acid.

Market Segmentation
By Company

• ICE
• Zhongshan Bailing
• Daewoong Chemical
• PharmaZell GmbH
• Dipharma Francis
• Suzhou Tianlv
• Sichuan Xieli
• Chuanning Bio
• Shilpa medicare
• Symbio generics
• Arch Pharma

Segment by Type

• Chemical Method
• Enzyme Method

Segment by Application

• Tablets
• Capsules
• Suspensions

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.